Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | RGS4 | P49798 | 2/20 | 0.38 |
| ▸ | RGS8 | P57771 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11499891 | 0.94 | MGLL (0.48) | HPGDKDM4EALDH1A1MAPTNPSR1 | |
| SCHEMBL6236352 | 0.92 | MGLL (0.52) | HPGDKDM4EALDH1A1MAPTNPSR1 | |
| SCHEMBL6232792 | 0.92 | MGLL (0.52) | HPGDKDM4EALDH1A1MAPTNPSR1 | |
| SCHEMBL1101454 | 0.88 | ALDH1A1 (0.47) | HPGDKDM4EALDH1A1MAPTNPSR1 | |
| SCHEMBL2728584 | 0.86 | KMT2A (0.44) | HPGDKDM4EALDH1A1MAPTNPSR1 | |
| SCHEMBL11499124 | 0.83 | MGLL (0.50) | HPGDKDM4EALDH1A1MAPTNPSR1 | |
| SCHEMBL11477209 | 0.82 | MEN1 (0.49) | HPGDKDM4EALDH1A1MAPTNPSR1 | |
| SCHEMBL1101255 | 0.80 | MGLL (0.53) | HPGDKDM4EALDH1A1MAPTNPSR1 | |
| SCHEMBL31716662 | 0.80 | ALDH1A1 (0.42) | HPGDKDM4EALDH1A1MAPTNPSR1 | |
| SCHEMBL11475404 | 0.79 | SMN1; SMN2 (0.45) | HPGDKDM4EALDH1A1MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0194226-B1 | A PHARMACEUTICAL COMPOSITION CONTAINING AN IMIDAZOLIDINETRIONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-02-07 | — | — | EP | claimed |
| EP-0194226-A1 | A pharmaceutical composition containing an imidazolidinetrione derivative or pharmaceutically acceptable salt thereof | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1986-09-10 | — | — | EP | claimed |
| CN-119192677-B | Composite heat stabilizer for PVC and preparation method | 深圳凯奇化工有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-119192677-A | Composite heat stabilizer for PVC and preparation method | 深圳凯奇化工有限公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-2632916-B1 | NOVEL ANTI-CANCER AGENTS | THE WALTER AND ELIZA HALL INST OF MEDICAL RES (AU) | 2017-01-11 | — | — | EP | disclosed |
| US-20160145243-A1 | Novel Anti-Cancer Agents | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2016-05-26 | — | — | US | disclosed |
| US-9221799-B2 | Anti-cancer agents | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2015-12-29 | — | — | US | disclosed |
| US-20150045365-A1 | Novel Anti-Cancer Agents | WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2015-02-12 | — | — | US | disclosed |
| US-8835629-B2 | Anti-cancer agents | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2014-09-16 | — | — | US | disclosed |
| US-20130261119-A1 | Novel Anti-Cancer Agents | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2013-10-03 | — | — | US | disclosed |
| EP-2632916-A1 | NOVEL ANTI-CANCER AGENTS | The Walter and Eliza Hall Institute of Medical Research (AU) | 2013-09-04 | — | — | EP | disclosed |
| US-6197806-B1 | USING A HYDANTOIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-1018339-A1 | Therapeutic agent for intractable vasculitis | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-12 | — | — | EP | disclosed |
| EP-0780125-A2 | Pharmaceutical composition containing a hydantoin derivative and use of said derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
| EP-0191735-B1 | NOVEL OXALURIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-09-12 | — | — | EP | disclosed |
| EP-0194226-B1 | A PHARMACEUTICAL COMPOSITION CONTAINING AN IMIDAZOLIDINETRIONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1990-02-07 | — | — | EP | disclosed |
| US-4708954-A | DIABETES-ORAL ADMINISTRATION | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1987-11-24 | — | — | US | disclosed |
| US-4683240-A | HYPOGLYCEMIC, HYPOUPIDEMIC | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1987-07-28 | — | — | US | disclosed |
| EP-0194226-A1 | A pharmaceutical composition containing an imidazolidinetrione derivative or pharmaceutically acceptable salt thereof | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1986-09-10 | — | — | EP | disclosed |
| EP-0191735-A2 | Novel oxaluric acid derivatives and pharmaceutical compositions containing them | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045365-A1 | Novel Anti-Cancer Agents | TP53, SLC10A1, HDAC6 | HPGD 604/4885KDM4E 2035/4885ALDH1A1 354/4885 |
| US-20130261119-A1 | Novel Anti-Cancer Agents | TP53, SLC10A1, ARFGAP1 | HPGD 639/4885KDM4E 2146/4885ALDH1A1 494/4885 |
| US-20160145243-A1 | Novel Anti-Cancer Agents | TP53, SLC10A1, HDAC6 | HPGD 604/4885KDM4E 2035/4885ALDH1A1 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.